How Are Regulatory Organizations Combating Limited Hemp Testing?

Uploaded June 2025 | Updated September 2026, 2 weeks ago

Morgan Keefer is the Senior Accreditation Officer at A2LA where she works with and assesses cannabis testing laboratories across the United States.

Since joining A2LA, Morgan has presented about Laboratory Shopping, Proficiency Testing, and Microbial Testing in the cannabis industry at Cannabis Science Conference, A2LA’s Annual Conference and PITTCON. At CannMed 25 she will present “Accredited Methods in Cannabis Testing” which will explore many of the challenges facing cannabis testing labs.

During our conversation we discuss:

The variation of cannabis testing regulations across the U.S., and how that creates challenges for multi-state labs and manufacturers.
The lack of established testing standards, which leads to inconsistent results across the industry
The role organizations like AOAC and USP play in creating standard methods
How inconsistent testing results affect consumer safety
The lack of testing requirements for consumable hemp products
Thank You to This Episode’s Sponsor: McKinney RSA

McKinney is made up of regulatory science veterans who apply lessons learned in the nicotine space to help cannabis manufacturers better understand the toxicological and societal implications of their product. They do that by Identifying base compounds, extracts, flavors and terpenes, understanding how they interact, and ensuring effectiveness for the intended use. They also provide dosing recommendations and establish guidelines for product consistency.

Learn more at mckinneyrsa.com

Additional Resources
* NIHC Verify program
* A2LA-NIHC Verify Hemp/Cannabis Recognition Program
* A2LA Domestic Recognitions
* A2LA Public Documents
* Register for CannMed 25 – cvent.me/emBPno
* Meet the CannMed 25 Speakers and Poster Presenters – cannmedevents.com/speakers –
* Review the Podcast – podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804
* CannMed Archive – cannmedevents.com/cannmed-video-archives

How Are Regulatory Organizations Combating Limited Hemp Testing? - Morgan Keefer

$Transforming Cannabidiol: Rational Design of Next-Generation CBD Analogues for Epilepsy -Luke Hodson Luke Hodson presents Transforming Cannabidiol: Rational Design of Next-Generation CBD Analogues for Epilepsy at CannMed 2026, covering CBD analogues, epilepsy treatment, and drug discovery. This work set out to develop a next-generation CBD analogue platform through rational scaffold engineering and targeted derivatization. The structural changes were designed to reduce CBDs major liabilities of CYP inhibition, poor solubility, rapid metabolism, and hepatic concerns, while preserving the key molecular interactions responsible for its antiseizure activity. A central design principle was to achieve higher and more sustained therapeutic brain concentrations, enabling predictable pharmacokinetics and once-daily oral dosing. More than 50 CBD analogues were generated using a scaffold-engineering strategy guided by known metabolic hotspots and physicochemical liabilities of cannabidiol. Structural modifications were selected to improve solubility, metabolic stability, CYP interaction profiles, and off-target safety. Analogues were evaluated in vitro for solubility, microsomal stability, CYP inhibition, hepatocyte viability, and receptor-level safety screens. Lead candidates underwent in vivo plasma and brain pharmacokinetic studies in mice. Antiseizure efficacy was assessed following oral administration across three validated preclinical seizure models. Exploratory hepatic and tolerability assessments supported translational evaluation. In vitro profiling showed that scaffold-engineered CBD analogues achieved substantial improvements in solubility, enhanced metabolic stability, and markedly reduced CYP inhibition across major isoforms, indicating a significantly lower drug-drug interaction risk. Exploratory safety assays demonstrated higher hepatocyte viability, cleaner hepatic biomarker profiles, and reduced off-target activity at cardiovascular, opioid, and cholinergic receptors, supporting a more favorable safety margin. These in vitro gains translated into major in vivo pharmacokinetic advantages. Lead analogues produced multi-fold increases in CNS exposure, up to six-fold higher brain concentrations than CBD, and improved brain-to-plasma ratios, resulting in more sustained and therapeutically relevant brain levels. PK profiles showed markedly lower inter-animal variability, yielding predictable exposure kinetics compatible with once-daily dosing. Improved exposure and preserved mechanistic interactions produced greater antiseizure potency and efficacy across three validated preclinical seizure models, including the MES assay. The optimized analogues achieved robust oral efficacy at lower doses due to higher and longer-lasting therapeutic brain concentrations. Together, these improvements support a broader therapeutic index and validate the scaffold-engineering strategy as a viable route for creating drug-like cannabidiol analogues. Rational synthetic derivatization and medicinal chemistry enabled the creation of next-generation CBD analogues that overcome major drug-like liabilities of cannabidiol while preserving the molecular features required for antiseizure activity. The resulting compounds show improved solubility, reduced CYP interactions, enhanced hepatic and off-target safety, and multi-fold increases in brain exposure with more predictable, once-daily pharmacokinetics. These advances produced superior oral antiseizure efficacy at lower doses and support this platform as a promising route for developing clinically viable cannabidiol-based therapeutics for refractory epilepsy. Learning Objectives: ⦿ Understand how scaffold-engineered CBD analogues improve solubility, metabolism, CYP and safety profiles, achieve higher and longer-lasting therapeutic brain levels, and support predictable once-daily oral dosing with strong anti-seizure efficacy Luke Hodson, PhD, is a medicinal chemist and translational drug discovery leader specializing in cannabinoid therapeutics for refractory epilepsy and neurosteroid therapeutics for traumatic brain injury. His work focuses on engineering next-generation small molecules that overcome poor solubility, rapid metabolism, CYP-mediated drug interactions, and hepatic liability to enable safer, more effective CNS treatments. At Sensa Neurosciences, Dr. Hodson serves as a Senior Scientist in Drug Discovery, contributing to medicinal chemistry strategy, structure-property optimization, and preclinical planning for next-generation cannabinoid therapeutics. This presentation was given at the CannMed 2026 Innovation & Collaboration Summit, held June 15-18 at the Hyatt Regency Lake Tahoe Resort. Visit cannmedevents.com to learn more.$

Synergistic Anticancer Activity of Cannabinoids & Terpenes in Triple Negative Breast Cancer

How Does CBG Interact with Standard Chemotherapies? - Mandip Sachdeva, PhD

Cannabigerol Potentiates Chemotherapy through Multi-Modal Tumor Suppression in Pancreatic Cancer

Recruitment Challenges for Cannabis Clinical Trials - Emily Lindley, PhD & Rachael Rzasa Lynn, MD

Preventing Opioid Overdose with Cannabinoids - Beth Weise, PhD

Frequently Identified Nonconformances Applicable to Cannabis Testing - Morgan Keefer

The National Cannabis Study with Ryan Vandrey, PhD & Johannes Thrul, PhD

Tissue Culture, Clonal Integrity & Regeneration Innovation

CBD increases the effectiveness of Naloxone?

What Work Has Been Done With Converting Novel Cannabinoids for Therapeutic Research? Mark Scialdone